Hemp-derived cannabinoids for menopause and perimenopause symptom relief
Official title: Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
Run by Washington State University · NCT07393672 · Data updated 2026-11-12
This will try hemp-derived cannabinoids versus placebo to see if they reduce physical and psychological symptoms in women aged 40–60 going through perimenopause or menopause.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 40 Years to 60 Years |
| Sex | Women only |
| Enrollment | 104 (estimated) |
| Sponsor | Washington State University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pullman, Washington) |
| Status | Recruiting |
| Started | February 11, 2026 |
| Main results expected | November 10, 2026 |
| Study ends | November 10, 2026 |
| Registry record updated | March 10, 2026 |
| Trial ID | NCT07393672 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women designated female at birth aged 40–60 who are perimenopausal or menopausal, are not regular cannabis users, are not taking excluded psychotropic medications, can use Zoom and a smartphone, and are willing to receive shipped study product are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have current severe depression or suicidality, psychosis or a family history of psychosis, are taking antidepressant/antipsychotic medications, or cannot abstain from other cannabis use are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, placebo-controlled 3-month trial tests hemp-derived minor cannabinoids (for example CBG and CBD) on symptoms of menopause and perimenopause in women aged 40–60. Participants complete an online screen, provide consent via an initial Zoom visit, and perform baseline cognitive tests before receiving product shipped directly from the manufacturer. Eligible participants are randomized to active cannabinoids or placebo and are asked to abstain from regular cannabis and avoid changing other medications or supplements during the study. Symptom reports and cognitive outcomes are collected remotely over the study period to compare active treatment with placebo.
Why it matters
Potential benefit: If successful, the cannabinoids could reduce menopausal physical and psychological symptoms and improve sleep and daily functioning for some women.
How similar studies have gone: Menopause-specific trials of cannabinoids are limited, and while some small studies and anecdotal reports suggest cannabinoids can help sleep, pain, and mood, this application for menopause remains relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * designated female at birth * 40-60 years of age * able to give informed consent (no intellectual disability) * stable pharmacotherapeutic regimen, no change in the past 3 months * abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months * abstinent for supplements, don't add any supplements (no changes in past 3 months) * own a smartphone * have access to Zoom on a secure, stable internet connection * perimenopausal or menopausal Exclusion Criteria: * currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication * severe depression, neurovegetative symptoms, or current suicidality * psychosis or family history of psychosis * pregnant or breastfeeding * chemotherapy * hypotension * drug testing for work or other reasons * illicit drug use in past 3 months (cannabis not illicit) * heavy alcohol use (4 drinks more than 4x/week) * international/air travel planned for more than one week in the next 3 months * cocounut allergy
Where it's running
-
Washington State University, Dept of Psychology
Pullman, Washington, United States Recruiting
Study contacts
- Study coordinator: Carrie Cuttler, PhD
- Email: carrie.cuttler@wsu.edu
- Phone: (509) 592-0151
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hop extract vs soy isoflavone for menopausal symptoms
This study tests whether a full-spectrum hop extract helps reduce menopausal mood symptoms better than soy isoflavones in peri- and postmenopausal women.
-
Lifestyle changes to ease menopausal symptoms, sleep problems, and anxiety
Researchers are testing whether a structured lifestyle education program helps perimenopausal and postmenopausal women see fewer menopausal symptoms, better sleep, and less anxiety compared to usual care.
-
CARAMEL: Personalizing Heart Risk in Women 40–60
This observational study tests a personalized cardiovascular risk-stratification approach for women aged 40–60 using multi-source data and a digital self-management tool.
-
Samphire Guided Care for Wellbeing at Work
This study tests a 12-week digital program with at-home neuromodulation to see if it helps women with menstrual or perimenopausal symptoms feel better at work and in daily life.
-
Low-level laser acupuncture to improve body shape and composition in overweight menopausal women
This trial will test whether adding low-level multi-acupoint laser acupuncture to WHO-recommended diet and exercise helps overweight or obese menopausal women lose weight and improve body composition.
-
16:8 time-restricted eating with a low glycaemic-index Mediterranean diet for perimenopausal and menopausal women
This trial will test whether a 16:8 time-restricted eating schedule combined with a low glycaemic-index Mediterranean diet can improve thinking, metabolic health, and biological ageing in women aged 45–75 in late perimenopause or menopause with BMI ≥23.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.